Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-05-18 08:58:42 UTC |
---|
Update Date | 2022-03-25 18:55:00 UTC |
---|
HMDB ID | HMDB0001935 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Warfarin |
---|
Description | Warfarin is an anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. |
---|
Structure | CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2 InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3 |
---|
Synonyms | Value | Source |
---|
Warfarine | Kegg | Choice | Kegg | (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin | HMDB | (Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine | HMDB | (S)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone | HMDB | 1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone | HMDB | 200 Coumarin | HMDB | 3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin | HMDB | 3-(Acetonylbenzyl)-4-hydroxycoumarin | HMDB | 3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin | HMDB | 3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin | HMDB | 3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin | HMDB | 4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine | HMDB | 4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin | HMDB | 4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine | HMDB | 4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin | HMDB | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | HMDB, MeSH | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one | HMDB | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin | HMDB | 4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine | HMDB | 4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine | HMDB | 4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine | HMDB | 4oh-Coumarin deriv. | HMDB | Arab rat death | HMDB | Arab rat deth | HMDB | Athrombin-K | HMDB | Athrombine-K | HMDB | Brumolin | HMDB | CO-Rax | HMDB | Compound 42 | HMDB | Coumadin | HMDB, MeSH | Coumafen | HMDB | Coumafene | HMDB | Coumaphen | HMDB | Coumaphene | HMDB | Coumarins | HMDB | Coumefene | HMDB | Cov-R-tox | HMDB | D-CON | HMDB | delta-CON | HMDB | Dethmor | HMDB | Dethnel | HMDB | Dicusat e | HMDB | DL-3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin | HMDB | Eastern states duocide | HMDB | fasco Fascrat powder | HMDB | Frass-ratron | HMDB | Killgerm sewarin P | HMDB | Kumader | HMDB | Kumadu | HMDB | Kumatox | HMDB | Kypfarin | HMDB | Latka 42 | HMDB | Liqua-tox | HMDB | Maag rattentod cum | HMDB | Mar-frin | HMDB | Martin'S mar-frin | HMDB | Maveran | HMDB | Mouse pak | HMDB | Place-pax | HMDB | Prothromadin | HMDB | Rat & mice bait | HMDB | Rat and mice bait | HMDB | Rat-a-way | HMDB | Rat-alpha-way | HMDB | Rat-b-gon | HMDB | Rat-beta-gon | HMDB | Rat-gard | HMDB | Rat-kill | HMDB | Rat-mix | HMDB | Rat-O-cide #2 | HMDB | Rat-O-cide no. 2 | HMDB | Rat-ola | HMDB | Rat-trol | HMDB | Ratorex | HMDB | Ratox | HMDB | Ratoxin | HMDB | Ratron | HMDB | Ratron g | HMDB | Rats-NO-more | HMDB | Ratten-koederrohr | HMDB | Rattenstreupulver neu schacht | HMDB | Rattenstreupulver new schacht | HMDB | Rattentraenke | HMDB | Rattunal | HMDB | RAX | HMDB | RCR Grey squirrel killer concentrate | HMDB | ro-Deth | HMDB | Rodafarin | HMDB | Rodafarin c | HMDB | Rodex | HMDB | Rodex blox | HMDB | Rosex | HMDB | Rough & ready mouse mix | HMDB | Rough and ready mouse mix | HMDB | Sakarat | HMDB | Sewarin | HMDB | Solfarin | HMDB | Sorexa plus | HMDB | Spray-trol brand roden-trol | HMDB | Temus W | HMDB | Tox-hid | HMDB | Twin light rat away | HMDB | Vampirinip II | HMDB | Vampirinip III | HMDB | Waran | HMDB | Warfarin sodium | HMDB, MeSH | Zoocoumarin | HMDB | aldo Brand OF warfarin sodium | MeSH, HMDB | apo-Warfarin | MeSH, HMDB | Apotex brand OF warfarin sodium | MeSH, HMDB | Bailly brand OF warfarin sodium | MeSH, HMDB | Boots brand OF warfarin sodium | MeSH, HMDB | Marevan | MeSH, HMDB | Aldocumar | MeSH, HMDB | Coumadine | MeSH, HMDB | Warfant | MeSH, HMDB | Bristol-myers squibb brand OF warfarin sodium | MeSH, HMDB | Genpharm brand OF warfarin sodium | MeSH, HMDB | Goldshield brand OF warfarin sodium | MeSH, HMDB | Sodium, warfarin | MeSH, HMDB | Tedicumar | MeSH, HMDB | Warfarin potassium | MeSH, HMDB | Antigen brand OF warfarin sodium | MeSH, HMDB | Estedi brand OF warfarin sodium | MeSH, HMDB | Gen-warfarin | MeSH, HMDB | Potassium, warfarin | MeSH, HMDB |
|
---|
Chemical Formula | C19H16O4 |
---|
Average Molecular Weight | 308.3279 |
---|
Monoisotopic Molecular Weight | 308.104859 |
---|
IUPAC Name | 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one |
---|
Traditional Name | warfarin |
---|
CAS Registry Number | 81-81-2 |
---|
SMILES | CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2 |
---|
InChI Identifier | InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3 |
---|
InChI Key | PJVWKTKQMONHTI-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton. |
---|
Kingdom | Organic compounds |
---|
Super Class | Phenylpropanoids and polyketides |
---|
Class | Coumarins and derivatives |
---|
Sub Class | Hydroxycoumarins |
---|
Direct Parent | 4-hydroxycoumarins |
---|
Alternative Parents | |
---|
Substituents | - 4-hydroxycoumarin
- Benzopyran
- 1-benzopyran
- Pyranone
- Monocyclic benzene moiety
- Benzenoid
- Pyran
- Heteroaromatic compound
- Vinylogous acid
- Ketone
- Lactone
- Oxacycle
- Organoheterocyclic compound
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 161 °C | Not Available | Boiling Point | 515.15 °C. @ 760.00 mm Hg (est) | The Good Scents Company Information System | Water Solubility | 0.017 mg/mL at 20 °C | Not Available | LogP | 2.70 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Warfarin,1TMS,isomer #1 | CC(=O)CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O | 2723.3 | Semi standard non polar | 33892256 | Warfarin,1TMS,isomer #1 | CC(=O)CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O | 2504.9 | Standard non polar | 33892256 | Warfarin,1TMS,isomer #1 | CC(=O)CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O | 3314.5 | Standard polar | 33892256 | Warfarin,1TMS,isomer #2 | CC(=CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2834.0 | Semi standard non polar | 33892256 | Warfarin,1TMS,isomer #2 | CC(=CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2674.0 | Standard non polar | 33892256 | Warfarin,1TMS,isomer #2 | CC(=CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3516.3 | Standard polar | 33892256 | Warfarin,1TMS,isomer #3 | C=C(CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2710.8 | Semi standard non polar | 33892256 | Warfarin,1TMS,isomer #3 | C=C(CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2592.4 | Standard non polar | 33892256 | Warfarin,1TMS,isomer #3 | C=C(CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3510.8 | Standard polar | 33892256 | Warfarin,2TMS,isomer #1 | CC(=CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2864.1 | Semi standard non polar | 33892256 | Warfarin,2TMS,isomer #1 | CC(=CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2699.0 | Standard non polar | 33892256 | Warfarin,2TMS,isomer #1 | CC(=CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3191.8 | Standard polar | 33892256 | Warfarin,2TMS,isomer #2 | C=C(CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2759.7 | Semi standard non polar | 33892256 | Warfarin,2TMS,isomer #2 | C=C(CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2598.9 | Standard non polar | 33892256 | Warfarin,2TMS,isomer #2 | C=C(CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3200.1 | Standard polar | 33892256 | Warfarin,1TBDMS,isomer #1 | CC(=O)CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O | 2973.3 | Semi standard non polar | 33892256 | Warfarin,1TBDMS,isomer #1 | CC(=O)CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O | 2708.4 | Standard non polar | 33892256 | Warfarin,1TBDMS,isomer #1 | CC(=O)CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O | 3409.3 | Standard polar | 33892256 | Warfarin,1TBDMS,isomer #2 | CC(=CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3119.2 | Semi standard non polar | 33892256 | Warfarin,1TBDMS,isomer #2 | CC(=CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 2890.7 | Standard non polar | 33892256 | Warfarin,1TBDMS,isomer #2 | CC(=CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3557.8 | Standard polar | 33892256 | Warfarin,1TBDMS,isomer #3 | C=C(CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 2996.9 | Semi standard non polar | 33892256 | Warfarin,1TBDMS,isomer #3 | C=C(CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 2798.4 | Standard non polar | 33892256 | Warfarin,1TBDMS,isomer #3 | C=C(CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3561.6 | Standard polar | 33892256 | Warfarin,2TBDMS,isomer #1 | CC(=CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3296.4 | Semi standard non polar | 33892256 | Warfarin,2TBDMS,isomer #1 | CC(=CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3118.0 | Standard non polar | 33892256 | Warfarin,2TBDMS,isomer #1 | CC(=CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3369.2 | Standard polar | 33892256 | Warfarin,2TBDMS,isomer #2 | C=C(CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3216.7 | Semi standard non polar | 33892256 | Warfarin,2TBDMS,isomer #2 | C=C(CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3002.7 | Standard non polar | 33892256 | Warfarin,2TBDMS,isomer #2 | C=C(CC(C1=CC=CC=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3384.2 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Warfarin EI-B (Non-derivatized) | splash10-014i-0293000000-848341bcbd6a3f0a2c6b | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Warfarin EI-B (Non-derivatized) | splash10-014i-0293000000-848341bcbd6a3f0a2c6b | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Warfarin GC-MS (Non-derivatized) - 70eV, Positive | splash10-0udl-3190000000-b963cb54bb6abedefbe3 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Warfarin GC-MS (1 TMS) - 70eV, Positive | splash10-00xr-7195000000-ca3a892fd51e0eac1242 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Warfarin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Warfarin GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Warfarin GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Warfarin GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-014i-7692000000-6e3993fee62d7eb7438e | 2018-05-25 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0429000000-1e818b579dc7a0fade2d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , negative-QTOF | splash10-03di-0900000000-f568338c06cd9b4762ac | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , negative-QTOF | splash10-03di-0900000000-acdd0ed19e403aa73c77 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-QFT , negative-QTOF | splash10-0bt9-0539000000-5b1c7c6c812ba72325e3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0009000000-e461e1aca7977a2838ad | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , positive-QTOF | splash10-0w29-0960000000-9fa099190280529cd891 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , positive-QTOF | splash10-00di-0910000000-d7dbaf6e7b34ee85e1f7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , positive-QTOF | splash10-03di-0920000000-4fb886a5c160afa86df9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-ITFT , positive-QTOF | splash10-03di-0920000000-ad608fe7680a2adf9d90 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin LC-ESI-QFT , positive-QTOF | splash10-0ik9-0942000000-5864f2d15892753d6a8b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 55V, Negative-QTOF | splash10-03di-0900000000-acdd0ed19e403aa73c77 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 55V, Positive-QTOF | splash10-0w29-0960000000-b5bc3614bc1379df068c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 35V, Negative-QTOF | splash10-0bt9-0539000000-3554db4e3651d4691cbb | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 75V, Positive-QTOF | splash10-0229-2900000000-022920b191a958c73833 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 60V, Positive-QTOF | splash10-07vi-5920000000-0506f7adccf44b63822a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 55V, Negative-QTOF | splash10-0a4i-0009000000-e461e1aca7977a2838ad | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 80V, Negative-QTOF | splash10-0a4i-0429000000-1e818b579dc7a0fade2d | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 75V, Positive-QTOF | splash10-0229-2900000000-6909a3446398afc7d421 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Warfarin 60V, Positive-QTOF | splash10-03kc-0910000000-b4521bf9a45fcfff36ac | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Warfarin 10V, Positive-QTOF | splash10-0a4l-0197000000-a98e039dbdc8da6c3b7c | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Warfarin 20V, Positive-QTOF | splash10-052f-0292000000-d9a969b41fe312282de6 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Warfarin 40V, Positive-QTOF | splash10-00di-2690000000-f20b105406ab790d37f0 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Warfarin 10V, Negative-QTOF | splash10-0a4i-1149000000-4072cf2742b0e6164f82 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Warfarin 20V, Negative-QTOF | splash10-0bt9-5988000000-eb075587f79ddb4af966 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Warfarin 40V, Negative-QTOF | splash10-052f-9350000000-47075e4967528dede6f3 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | 2018-05-25 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Membrane (predicted from logP)
|
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00682 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00682 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 10442445 |
---|
KEGG Compound ID | C01541 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Not Available |
---|
METLIN ID | Not Available |
---|
PubChem Compound | Not Available |
---|
PDB ID | Not Available |
---|
ChEBI ID | 87732 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | rw1136391 |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004 Feb 5;427(6974):537-41. [PubMed:14765194 ]
- Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature. 2004 Feb 5;427(6974):541-4. [PubMed:14765195 ]
- Whitlon DS, Sadowski JA, Suttie JW: Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978 Apr 18;17(8):1371-7. [PubMed:646989 ]
- Freedman MD: Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol. 1992 Mar;32(3):196-209. [PubMed:1564123 ]
- Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003 May 7;41(9):1633-52. [PubMed:12742309 ]
- Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):204S-233S. [PubMed:15383473 ]
- Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS: Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005 May 23;165(10):1095-106. [PubMed:15911722 ]
- Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):160S-198S. doi: 10.1378/chest.08-0670. [PubMed:18574265 ]
- (). Loftus, Christopher M. (1995). Fetal toxicity of common neurosurgical drugs. Neurosurgical Aspects of Pregnancy. Park Ridge, Ill: American Association of Neurological Surgeons. pp. 11-3.. .
- (). Macina, Orest T.; Schardein, James L. (2007). Warfarin. Human Developmental Toxicants. Boca Raton: CRC Taylor & Francis. pp. 193-4. .
|
---|